Prostate cancer is a life-threatening disease that occurs when cells in the prostate gland start to grow uncontrollably, forming a tumour. However, many cases of prostate cancer are slow-growing and ...
A phase 1b/2 study to evaluate the safety and efficacy of igermetostat (XNW5004) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. This is an ASCO ...
A molecular imaging tool developed by researchers at the University of California’s two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...
High energy proton beam therapy, an advanced form of radiotherapy, made its debut in the UK in 2018. Both the NHS and private clinics began offering this treatment in the same year, but they treated ...
SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...
Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...
A new cohort study included 778 men with prostate cancer who had received either radiation or surgery within 1 year of diagnosis. Patients who lived in rural areas had nearly twice the rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results